The global xerostomia (dry mouth disease) therapeutics market size reached US$ 739.8 Million in 2023. Looking forward, the publisher expects the market to reach US$ 985.0 Million by 2032, exhibiting a growth rate (CAGR) of 3.23% during 2023-2032.
Xerostomia, or dry mouth, refers to symptoms or sensations of oral dryness that are usually caused due to a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, and Alzheimer’s disorder. It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips.
Apart from this, the early diagnosis of salivary glands by practitioners and the usage of recommended mouth moisturizing products, such as over-the-counter (OTC) rinsing, can assist in lubricating the mouth. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, and mitigate bad breath and taste disorders. Consequently, xerostomia therapeutics are used across several hospitals and clinics to deal with decreased salivary gland function.
Moreover, the favorable initiatives being commenced by governments to sensitize consumers regarding the xerostomia disease, its symptoms, causes, and treatments are impelling the market growth. Apart from this, the easy availability of various therapeutic drugs and ongoing research and development (R&D) activities are creating a positive outlook for the market.
2. What is the expected growth rate of the global xerostomia (dry mouth disease) therapeutics market during 2024-2032?
3. What are the key factors driving the global xerostomia (dry mouth disease) therapeutics market?
4. What has been the impact of COVID-19 on the global xerostomia (dry mouth disease) therapeutics market?
5. What is the breakup of the global xerostomia (dry mouth disease) therapeutics market based on type?
6. What is the breakup of the global xerostomia (dry mouth disease) therapeutics market based on the drug type?
7. What is the breakup of the global xerostomia (dry mouth disease) therapeutics market based on the distribution channel?
8. What are the key regions in the global xerostomia (dry mouth disease) therapeutics market?
9. Who are the key players/companies in the global xerostomia (dry mouth disease) therapeutics market?
Xerostomia, or dry mouth, refers to symptoms or sensations of oral dryness that are usually caused due to a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, and Alzheimer’s disorder. It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips.
Apart from this, the early diagnosis of salivary glands by practitioners and the usage of recommended mouth moisturizing products, such as over-the-counter (OTC) rinsing, can assist in lubricating the mouth. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, and mitigate bad breath and taste disorders. Consequently, xerostomia therapeutics are used across several hospitals and clinics to deal with decreased salivary gland function.
Xerostomia (Dry Mouth Disease) Therapeutics Market Trends:
The increasing incidences of dry mouth, especially amongst the geriatric population, due to medicine side-effects of radiotherapy and chemotherapy and the rising need for dry mouth relief products are primarily driving the market growth. Additionally, the growing uptake of several prescription-based toothpaste, vitamin gummies, and medicines for treating Sjogren’s syndrome, Alzheimer’s diseases, and human immunodeficiency virus (HIV) that cause xerostomia is acting as another growth-inducing factor. In line with this, the rising consumer awareness regarding the early diagnosis of xerostomia, significant enhancements in healthcare expenditure, and the advent of diverse diagnostic technologies are propelling the market growth.Moreover, the favorable initiatives being commenced by governments to sensitize consumers regarding the xerostomia disease, its symptoms, causes, and treatments are impelling the market growth. Apart from this, the easy availability of various therapeutic drugs and ongoing research and development (R&D) activities are creating a positive outlook for the market.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global xerostomia (dry mouth disease) therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug type and distribution channel.Breakup by Type:
- Artificial Saliva/Saliva Substitutes
- Salivary Stimulants
Breakup by Drug Type:
- OTC
- Prescription
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).Key Questions Answered in This Report
1. How big is the global xerostomia (dry mouth disease) therapeutics market?2. What is the expected growth rate of the global xerostomia (dry mouth disease) therapeutics market during 2024-2032?
3. What are the key factors driving the global xerostomia (dry mouth disease) therapeutics market?
4. What has been the impact of COVID-19 on the global xerostomia (dry mouth disease) therapeutics market?
5. What is the breakup of the global xerostomia (dry mouth disease) therapeutics market based on type?
6. What is the breakup of the global xerostomia (dry mouth disease) therapeutics market based on the drug type?
7. What is the breakup of the global xerostomia (dry mouth disease) therapeutics market based on the distribution channel?
8. What are the key regions in the global xerostomia (dry mouth disease) therapeutics market?
9. Who are the key players/companies in the global xerostomia (dry mouth disease) therapeutics market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Xerostomia (Dry Mouth Disease) Therapeutics Market
6 Market Breakup by Type
7 Market Breakup by Drug Type
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- 3M Company
- Biotene (GSK plc)
- Parnell Pharmaceuticals Inc.
- Quest Products LLC
- Saliwell Ltd
- Sun Pharmaceutical Industries Limited
- West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 739.8 Million |
| Forecasted Market Value ( USD | $ 985 Million |
| Compound Annual Growth Rate | 3.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
